Inpact activities
The Inpact project brings together a multidisciplinary network of researchers dedicated to advancing the development of innovative peptide-based therapeutics. By combining expertise in oncology and infectious disease, the consortium explores the potential of chimeric molecules that fuse antitumoural and antimicrobial properties. These novel compounds are designed to overcome biological barriers and improve targeted delivery, offering a promising avenue for next-generation drug development. Through collaborative staff exchanges and shared training initiatives, the network fosters a dynamic environment where scientific discovery translates directly into tangible biomedical progress.
A central pillar of the Inpact initiative is the creation of proof-of-concept studies that validate the therapeutic potential of peptide chimeras. Researchers work to engineer molecules capable of recognising and neutralising both cancer cells and pathogenic bacteria simultaneously. This dual-action approach addresses the growing challenge of multidrug-resistant infections in immunocompromised patients. By refining peptide sequences and evaluating their stability, efficacy, and safety profiles, the consortium lays the groundwork for future clinical applications. Each successful proof-of-concept study brings the platform technology closer to real-world pharmaceutical use.
Training and career development are fundamental to the Inpact mission, as the programme invests in the next generation of scientists. Early-stage and experienced researchers alike benefit from cross-sector secondments between academic institutions and biopharmaceutical companies. These exchanges provide hands-on exposure to drug discovery workflows, from peptide design and synthesis to preclinical evaluation and regulatory strategy. The result is a highly skilled workforce equipped to navigate the complex landscape of modern drug development. Such training ensures that the knowledge generated within the consortium continues to drive innovation long after the project concludes.
Dissemination and communication activities ensure that Inpact findings reach a broad audience beyond the laboratory. Researchers share their progress through peer-reviewed publications, scientific conferences, and public engagement events designed to raise awareness about peptide-based therapies. Special attention is given to explaining the societal benefits of developing new antimicrobial and anticancer agents. By maintaining transparent and accessible communication channels, the consortium builds trust with stakeholders, including patients, healthcare professionals, and policy makers. This commitment to outreach amplifies the impact of the research and encourages continued investment in innovative biomedical science.
The long-term vision of Inpact extends to positioning novel peptide drugs for market entry and clinical adoption. Through strategic partnerships with pharmaceutical companies, the consortium works to bridge the gap between academic discovery and commercial product development. Intellectual property generated during the project is carefully managed to support future licensing and technology transfer opportunities. By targeting specific unmet medical needs in oncology and infectious disease, the platform technology aims to deliver tangible benefits to patients worldwide. This translational focus ensures that the science pursued today becomes the treatment option of tomorrow.
